Edition:
United States

Acorda Therapeutics Inc (ACOR.OQ)

ACOR.OQ on NASDAQ Stock Exchange Global Select Market

23.25USD
1:21pm EDT
Change (% chg)

$0.35 (+1.53%)
Prev Close
$22.90
Open
$22.90
Day's High
$23.50
Day's Low
$22.75
Volume
25,875
Avg. Vol
168,692
52-wk High
$29.50
52-wk Low
$13.65

Chart for

About

Acorda Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on developing therapies that restore function and improve the lives of people with neurological disorders. As of December 31, 2016, the Company marketed three United States Food and Drug Administration (FDA)-approved therapies, including Ampyra... (more)

Overall

Beta: 1.56
Market Cap(Mil.): $1,083.71
Shares Outstanding(Mil.): 46.91
Dividend: --
Yield (%): --

Financials

  ACOR.OQ Industry Sector
P/E (TTM): -- 173.69 32.21
EPS (TTM): -4.55 -- --
ROI: -18.69 -0.70 13.05
ROE: -35.49 -2.69 14.90

BRIEF-Axsome Therapeutics Appoints Nick Pizzie, Cpa, Mba, As Chief Financial Officer

* AXSOME THERAPEUTICS APPOINTS NICK PIZZIE, CPA, MBA, AS CHIEF FINANCIAL OFFICER

Apr 19 2018

BRIEF-Abeona Therapeutics Appoints Carsten Thiel, Ph.D., As Chief Executive Officer

* ABEONA THERAPEUTICS APPOINTS CARSTEN THIEL, PH.D., AS CHIEF EXECUTIVE OFFICER

Apr 02 2018

BRIEF-Acorda Files Marketing Authorization Application For Inbrija

* ACORDA FILES MARKETING AUTHORIZATION APPLICATION FOR INBRIJA™ (LEVODOPA INHALATION POWDER)

Mar 26 2018

BRIEF-Leap Therapeutics Provides Dkn-01 Program Update

* LEAP THERAPEUTICS PROVIDES DKN-01 PROGRAM UPDATE AND ANNOUNCES SCIENTIFIC PRESENTATIONS AT AACR ANNUAL MEETING

Mar 14 2018

BRIEF-Acorda Enters Into Cooperation Agreement With Scopia

* ACORDA THERAPEUTICS INC - ‍ UNDER TERMS, AFTER 2018 ANNUAL MEETING AND UNTIL JAN 1, 2019, SCOPIA IS ENTITLED TO APPOINT 2 DIRECTORS TO CO'S BOARD​

Feb 28 2018

BRIEF-Acorda Announces FDA Acceptance Of New Drug Application For Inbrija

* ACORDA ANNOUNCES FDA ACCEPTANCE OF NEW DRUG APPLICATION FOR INBRIJA™ (LEVODOPA INHALATION POWDER)

Feb 20 2018

BRIEF-Acorda Therapeutics Q4 Adj Shr $0.61

* AMPYRA NET REVENUE IS EXPECTED TO BE $330 MILLION TO $350 MILLION IN 2018

Feb 15 2018

Acorda Therapeutics exploring sale: WSJ

Acorda Therapeutics is exploring a sale of the company, the Wall Street Journal reported, citing people familiar with the matter.

Jan 05 2018

BRIEF-Acorda Therapeutics Is Exploring A Potential Sale - WSJ, Citing Sources

* ACORDA THERAPEUTICS IS EXPLORING A POTENTIAL SALE - WSJ, CITING SOURCES Source text - http://on.wsj.com/2Ay49BA Further company coverage: (Bengaluru Newsroom)

Jan 05 2018

BRIEF-Acorda Resubmits New Drug Application For INBRIJA

* ACORDA RESUBMITS NEW DRUG APPLICATION FOR INBRIJA™ (CVT-301, LEVODOPA INHALATION POWDER)

Dec 07 2017

Earnings vs. Estimates